Automate Your Wheel Strategy on ABBV
With Tiblio's Option Bot, you can configure your own wheel strategy including ABBV - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ABBV
- Rev/Share 32.4474
- Book/Share 0.8269
- PB 235.7043
- Debt/Equity 49.2176
- CurrentRatio 0.7602
- ROIC 0.1793
- MktCap 334397184000.0
- FreeCF/Share 8.7019
- PFCF 21.7353
- PE 79.7855
- Debt/Assets 0.5133
- DivYield 0.0342
- ROE 0.9559
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | ABBV | Citigroup | Buy | Neutral | -- | $205 | May 14, 2025 |
| Initiation | ABBV | Cantor Fitzgerald | -- | Overweight | -- | $210 | April 22, 2025 |
| Resumed | ABBV | BofA Securities | -- | Neutral | -- | $191 | Dec. 10, 2024 |
| Downgrade | ABBV | Daiwa Securities | Outperform | Neutral | -- | $180 | Dec. 5, 2024 |
| Initiation | ABBV | Bernstein | -- | Market Perform | -- | $203 | Oct. 17, 2024 |
News
AbbVie (ABBV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
AbbVie (ABBV) Tops Q2 Earnings and Revenue Estimates
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Positive
AbbVie (ABBV) came out with quarterly earnings of $2.97 per share, beating the Zacks Consensus Estimate of $2.89 per share. This compares to earnings of $2.65 per share a year ago.
Read More
Sell AbbVie Stock Ahead of Its Upcoming Earnings?
Published: July 30, 2025 by: Forbes
Sentiment: Negative
AbbVie (NYSE:ABBV) is scheduled to release its earnings report on Thursday, July 31, 2025. For event-driven traders, understanding historical stock performance around earnings announcements can be a valuable tool.
Read More
AbbVie Announces Positive Topline Results from Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ®) for Alopecia Areata
Published: July 30, 2025 by: PRNewsWire
Sentiment: Neutral
In Study 2 of the pivotal Phase 3 UP-AA clinical program, upadacitinib (RINVOQ®) achieved the primary endpoint, demonstrating that 44.6% and 54.3% of patients with severe alopecia areata treated with upadacitinib 15 mg and 30 mg, respectively, reached 80% or more scalp hair coverage at week 24 as defined by the severity of alopecia tool (SALT) score ≤ 201 Key secondary endpoints, including improvements in eyebrows and eyelashes, as well as the percentage of subjects with 90% or more scalp coverage (SALT ≤ 10) and complete scalp hair coverage (SALT=0) at week 24, were also met1 The safety profile in …
Read More
4 Safe High-Yielding Dividend Aristocrats Are Our Top Picks in a Dangerous Market
Published: July 30, 2025 by: 24/7 Wall Street
Sentiment: Positive
Investors seeking defensive companies that pay substantial dividends are drawn to the Dividend Aristocrats, and with good reason.
Read More
Top 10 Income Funds From Eaton Vance
Published: July 29, 2025 by: Seeking Alpha
Sentiment: Positive
Eaton Vance's top taxable closed-end funds offer reliable monthly income, strong long-term returns, and are managed by highly skilled teams with proven track records. I prioritize funds trading at a discount to NAV with distribution yields near or above 8%, focusing on both income and capital appreciation potential. For total return, EOS and EOI are top picks; for dividend income, EVT (domestic) and ETG (global) provide diversification and attractive yields.
Read More
Pre-Q2 Earnings: Is AbbVie Stock a Portfolio Must-Have?
Published: July 28, 2025 by: Zacks Investment Research
Sentiment: Positive
ABBV's Q2 results are likely to hinge on Skyrizi and Rinvoq growth as Humira declines, with 2025 set for a strong revenue rebound.
Read More
Will These 5 Pharma/Biotech Bigwigs Surpass Q2 Earnings Forecasts?
Published: July 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Let's look at five biotech and drug companies, MRK, AZN, BMY, ABBV and MRNA, slated to release their second-quarter 2025 results this week.
Read More
AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Neutral
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Final Trades: Abbvie, Uber, Western Union and Live Nation
Published: July 23, 2025 by: CNBC Television
Sentiment: Neutral
(OPTIMIZED VIDEO SPECIFIC DESCRIPTION)
Read More
4 Reasons To Buy AbbVie
Published: July 22, 2025 by: Seeking Alpha
Sentiment: Neutral
I maintain my Buy rating on AbbVie, emphasizing its medium-to-long-term potential despite recent outlook downgrades and tariff risks. Recent guidance cuts are minor and don't meaningfully undermine the investment case; with earnings growth expected in Q2 2025. The company's dividends add to its attractiveness at an uncertain time, adding to robust price returns over time.
Read More
How Will AbbVie's Neuroscience Franchise Perform in Q2 Earnings?
Published: July 22, 2025 by: Zacks Investment Research
Sentiment: Positive
ABBV's neuroscience sales are projected to jump 15% in Q2, driven by Botox Therapeutic, Vraylar and oral migraine drug gains.
Read More
Best Dividend Kings: July 2025
Published: July 22, 2025 by: Seeking Alpha
Sentiment: Positive
14 Dividend Kings continue to outperform the S&P 500 in 2025. Dividend growth remains healthy, with one recent increase and a collective 2025 growth rate of 5.23%. Seventeen Dividend Kings currently appear undervalued with strong long-term return potential, using Dividend Yield Theory for valuation.
Read More
July's 5 Dividend Growth Stocks With Yields Up To 7.96%
Published: July 18, 2025 by: Seeking Alpha
Sentiment: Positive
Dividend growth stocks can offer a stable way to passively grow one's income, creating long-term compounding wealth over the long run. Today, we are looking at a screening process that focuses on higher yields but ranks higher on dividend safety and consistency for growth. From the hundreds that end up listed, we take a look at some of those that rank on the higher yield end for an initial look.
Read More
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
Published: July 18, 2025 by: Zacks Investment Research
Sentiment: Positive
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
AbbVie (ABBV) Surpasses Market Returns: Some Facts Worth Knowing
Published: July 16, 2025 by: Zacks Investment Research
Sentiment: Positive
The latest trading day saw AbbVie (ABBV) settling at $190.58, representing a +2.25% change from its previous close.
Read More
How Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?
Published: July 16, 2025 by: Zacks Investment Research
Sentiment: Negative
ABBV's oncology sales might have dipped in Q2 as gains from newer drugs face pressure from Imbruvica's ongoing decline.
Read More
Here's How to Play AbbVie Stock as it Reaches Golden Cross
Published: July 15, 2025 by: Zacks Investment Research
Sentiment: Positive
ABBV hits a bullish golden cross as Skyrizi and Rinvoq drive growth, offsetting Humira losses and aesthetic headwinds.
Read More
ABBV or BMY: Which Biopharma Giant Has Better Prospects for Now?
Published: July 11, 2025 by: Zacks Investment Research
Sentiment: Negative
AbbVie edges ahead of Bristol Myers with strong Skyrizi and Rinvoq growth, offsetting Humira declines and portfolio headwinds.
Read More
A Sweet Spot Between Yield And Growth: The Best Balanced Dividend Growers For 2025
Published: July 11, 2025 by: Seeking Alpha
Sentiment: Positive
This isn't a buy list. It's a shortlist to help you speed up your research. We've included both U.S. and Canadian names, organized by country. Each company comes with a business summary, plus a bull and bear case to help you assess the fit. Comcast benefits from diversified cash flow through broadband, content creation, and international operations. The business remains cyclical—recessions hit industrial demand, and European expansion poses integration risks. Brand power and wide distribution provide resilience. PepsiCo is expanding its healthier product lines and boosting e-commerce. The shift toward healthier foods poses a threat to legacy products.
Read More
Final Trades: Abbvie, Boeing, Oracle and Joby Aviation
Published: July 10, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee give you their top stocks to watch for the second half.
Read More
Trump threatens impose up to 200% tariff on pharmaceuticals 'very soon'
Published: July 08, 2025 by: CNBC
Sentiment: Neutral
President Donald Trump threatened to impose up to 200% tariffs on pharmaceuticals imported into the U.S. "very soon." But he suggested that those levies would not go into effect immediately, saying he will "give people about a year, year and a half.
Read More
How Will Skyrizi and Rinvoq Sales Aid AbbVie's Upcoming Q2 Results?
Published: July 08, 2025 by: Zacks Investment Research
Sentiment: Neutral
ABBV leans on Skyrizi and Rinvoq sales strength to offset Humira's decline ahead of its Q2 earnings report.
Read More
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
Published: July 07, 2025 by: Zacks Investment Research
Sentiment: Positive
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Is It Worth Investing in AbbVie (ABBV) Based on Wall Street's Bullish Views?
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Positive
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Read More
AbbVie Stock At $190: Premium Pricing For A Transformation Story
Published: July 02, 2025 by: Forbes
Sentiment: Positive
AbbVie (NASDAQ:ABBV) has distinguished itself as one of the top performers in the healthcare sector this year, with its stock rising by 6% while the broader S&P 500 healthcare index fell by 1%. This outperformance is indicative of investor confidence in the pharmaceutical giant's ambitious transformation strategy as it navigates the post-Humira period.
Read More
Why AbbVie (ABBV) is a Top Value Stock for the Long-Term
Published: July 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Will AbbVie's Acquisition Spree Aid Pipeline Growth?
Published: July 02, 2025 by: Zacks Investment Research
Sentiment: Neutral
ABBV's $2.1 billion Capstan deal and 20+ recent acquisitions sharpen its pipeline edge across immunology and beyond.
Read More
ABBV to Boost Immunology Pipeline With Capstan Buyout for $2.1B
Published: July 01, 2025 by: Zacks Investment Research
Sentiment: Positive
AbbVie's $2.1 billion Capstan deal brings a novel in-vivo CAR-T therapy and tLNP platform to boost its immunology pipeline.
Read More
Abbvie confirms $2.1bn Capstan swoop
Published: June 30, 2025 by: Proactive Investors
Sentiment: Positive
Abbvie Inc (NYSE:ABBV) has agreed to acquire Capstan Therapeutics in a deal worth up to $2.1 billion, expanding its pipeline with a potential first-in-class treatment for autoimmune diseases and gaining access to a new type of RNA delivery system. The acquisition will give the pharma giant control of CPTX2309, a lipid nanoparticle-based therapy that delivers mRNA directly into the body to program the immune system.
Read More
About AbbVie Inc. (ABBV)
- IPO Date 2013-01-02
- Website https://www.abbvie.com
- Industry Drug Manufacturers - General
- CEO Robert A. Michael CPA
- Employees 55000